AI Chips Today - AI Boosts Cancer Drug Discovery Through Innovative Techniques

Rakovina Therapeutics Inc. has presented promising data at the 2025 Society for Neuro-Oncology Annual Meeting, demonstrating advancements in their AI-derived PARP1 inhibitor program. Utilizing AI methods such as Deep Docking™ and generative AI, the company has been able to effectively screen large chemical libraries, resulting in the discovery of novel, CNS-penetrant, PARP1-selective small molecules. These compounds have undergone biochemical evaluations, with a subset showing favorable drug-like properties and potential for CNS penetration. This progress underscores the role of AI in enhancing drug discovery processes, specifically in the development of innovative cancer therapies with improved selectivity and pharmacokinetic profiles.

In other trading, NAURA Technology Group (SZSE:002371) was a notable mover up 7.6% and finishing the session at CN¥416.24. At the same time, Advantest (TSE:6857) lagged, down 12.1% to finish the session at ¥18,315.

Advantest's expansion into AI-driven markets may significantly boost its profits soon. Discover the full narrative on this strategic growth opportunity by clicking here.

As a reminder, check out our recent Market Insights article, where we urgently highlighted potential risks beneath the AI chips surge, driven by circular financing.

Best AI Chip Stocks

• Micron Technology (NasdaqGS:MU) finished trading at $207.37 up 3%.
• NVIDIA (NasdaqGS:NVDA) closed at $178.88 down 1%.
• Advanced Micro Devices (NasdaqGS:AMD) settled at $203.78 down 1.1%.

Taking Advantage

• Reveal the 67 hidden gems, such as NXP Semiconductors, OmniVision Integrated Circuits Group and Piotech, among our AI Chip Stocks screener with a single click here.
• Ready For A Different Approach? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Sources:

• Simply Wall St
• "Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting" from Rakovina Therapeutics Inc on GlobeNewswire (published 24 November 2025)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com